Greece's Medical Cannabis Boom Meets Unchanged Recreational Penalties

August 27, 2026

Photo via Pexels.

Stand in a pharmacy in Kalamata and you can now buy cannabis oil grown forty minutes down the road in Examilia, packaged for export abroad as easily as it is dispensed to a Greek patient with a prescription. Stand on a street corner in Athens with a joint in your pocket, though, and you're still looking at a misdemeanor charge under a law written in 2013, before any of that pharmacy shelf existed. Greece has spent the better part of a decade building a genuinely competitive medical cannabis export business, one now projected to nearly double in value year over year. It has done almost nothing, in that same stretch of time, to touch the criminal penalties that apply to the ordinary citizen caught with a gram of the same plant.

That gap is not an oversight. It is the product of two entirely separate policy tracks that Athens has allowed to run in parallel without ever forcing them to meet. One track is industrial: licensing, EU export certification, greenhouse square footage, quarterly shipment tonnage. The other is criminal law, largely untouched since well before legalization, still built around suspicion and prosecution rather than public health. Greece is a useful case study precisely because the contradiction is so stark and so well documented — a country that will happily sell you the plant if you're a patient abroad, but will still charge you with a crime if you're a citizen in Piraeus.

From Schedule A to a $46.8 Million Export Industry

Photo via Unsplash.

Greece's medical cannabis industry starts with a scheduling change that got surprisingly little international attention when it happened. In 2017, under pressure from the patient advocacy group MAMAKA, whose members had spent years lobbying for access to cannabis-based treatment for conditions ranging from chronic pain to epilepsy, the Greek government moved cannabis from Schedule A — the strictest category, reserved for substances deemed to have no medical value — to Schedule D. That reclassification was the legal hinge the entire industry now swings on. Without it, none of what followed was possible under Greek law.

Law 4523/2018 turned that scheduling change into an actual licensing regime, setting out how companies could apply to cultivate, process and eventually distribute cannabis for medical use. Amendments between 2021 and 2023 filled in details around cultivation standards, security requirements and processing facility specifications, gradually building something closer to a functioning industrial framework rather than a paper law. The results are now showing up in market data: Greece's medical cannabis sector was valued at roughly $32 million in 2025, with projections putting it at $46.8 million in 2026 — nearly 50 percent growth in a single year, which is an aggressive trajectory for a market this young.

The detail that makes the whole thing structurally unusual is a 2021 amendment to Law 4139/2013 that banned medical cannabis imports outright. Every gram of product sold in Greece, whether to a domestic patient or shipped abroad, has to be grown and processed on Greek soil. That's not how most emerging medical cannabis markets operate — many countries lean on imports from established producers like Canada or the Netherlands to bridge the gap while domestic cultivation scales up. Greece cut off that option entirely, which sounds like a boon for domestic agriculture but actually created years of bottleneck, since it meant no patient could be treated until Greek-grown product cleared every regulatory step from seed to pharmacy shelf.

Tikun Olam and the Seven-Year Wait for Pharmacy Shelves

Photo by cottonbro studio via Pexels.

The practical consequence of the import ban was a seven-year wait. Greece legalized medical cannabis in 2017, but the first prescription wasn't filled at a Greek pharmacy until February 19, 2024. For patients with a doctor's recommendation and a real diagnosis, that's not a bureaucratic footnote — it's seven years of being legally entitled to a treatment that simply didn't exist on any shelf they could reach.

The company that finally closed that gap is Tikun Olam, the Israeli cannabis firm with decades of cultivation experience, which built out its Greek operation at a facility in Examilia, near Corinth. The scale is substantial for a market this size: 56,000 square meters total, including a 16,000 square meter greenhouse, a 1,000 square meter primary processing unit and a 1,500 square meter packaging facility. This isn't a boutique operation testing the waters — it's built for volume and export from day one.

That export ambition materialized quickly once product started moving. Tikun Olam shipped its first exports out of Greece to Switzerland in November 2024, just months after Greek patients themselves got access. By the first quarter of 2025, Greece had exported 49 kilograms of medical cannabis to Germany alone — a meaningful number for a market that had, functionally, only existed for a year.

Put those two facts together and the strategy becomes obvious: Greece never intended to simply supply itself. The domestic-production mandate that forced years of delay also means Greece controls its entire supply chain, with no reliance on foreign growers and full authority to certify product for EU export. Germany, with its large and growing medical cannabis patient population, is an obvious target market, and Switzerland's early orders suggest interest beyond the EU's own borders. Greece is positioning itself as a grower and exporter to the rest of Europe, leaning on Mediterranean growing conditions and comparatively lower production costs to compete with established players elsewhere on the continent.

The 2026 Crackdown: Higher THC Limit, Total Flower Ban

Just as the export business was gathering momentum, Greece's domestic consumer rules took a sharp turn in the opposite direction. In April 2026, the Health Ministry opened public consultation on a draft law covering cannabis, nicotine and tobacco products together, with the consultation window closing April 27, 2026. Bundling cannabis policy in with tobacco and nicotine regulation was itself a signal of how the government wanted the issue framed — as a matter of public health control rather than agricultural or medical policy.

The substance of the bill contained a genuine contradiction. It raised the legal THC threshold for hemp products from 0.2% to 0.3%, aligning Greece with the EU's broader shift toward the higher limit that most member states have already adopted for industrial hemp. But in the same bill, it banned the retail sale, supply, purchase and use of dried cannabis flower entirely — even flower that fell within that newly raised legal THC limit. In effect, lawmakers loosened the potency threshold with one hand while eliminating the product category that threshold was meant to govern with the other.

The bill moved fast once it reached Parliament. It was tabled in the Hellenic Parliament on May 5, 2026, and became Law 5302/2026 shortly after, published in Government Gazette 78/A on May 20, 2026. The practical effect for Greek retailers was immediate: CBD and hemp flower products that had been sold openly in shops around Athens, Thessaloniki and tourist areas across the islands were no longer legally sellable at all.

Enforcement followed the same speed. The National Organization for Medicines, Greece's regulatory body for medicines and related products (known by its Greek acronym EOF), ordered businesses to immediately halt sales, circulation and supply of the affected products. Inspectors began checking retail compliance shortly after the law's publication, leaving hemp shop owners with essentially no transition period to clear existing inventory or adjust their business models.

A Law Greece's Own Advisory Body Says Breaks EU Rules

Photo via Pexels.

The speed of Law 5302/2026's passage didn't stop Greece's own institutions from objecting to it. The OKE — the Economic and Social Council of Greece, the country's statutory advisory body on economic and labor legislation — issued a formal opinion concluding that the bill does not comply with EU law governing the free movement of goods. That's a serious charge for a government advisory body to level at its own Parliament's legislation, and it points to a real legal vulnerability rather than a political talking point.

The specific problem is procedural as much as substantive. EU Directive 2015/1535, administered through the TRIS notification system, requires member states to give advance notice of technical regulations that could affect trade in the single market — before those regulations are enacted, not after. Greece appears to have skipped that notification step entirely when moving Law 5302/2026 through Parliament. Historically, failure to notify under TRIS has left member states exposed to legal challenges, and in prior cases across the EU, unnotified technical rules have been ruled unenforceable against traders based in other member states. That precedent matters here: if a Dutch or German hemp company wanted to test Greece's flower ban in court, the TRIS gap could be their strongest argument.

The underlying tension is one Greece created for itself. It wants to be seen across Europe as a trustworthy medical cannabis exporter, operating inside EU pharmaceutical and agricultural standards with the paperwork to prove it. At the same time, it just enacted a domestic consumer product rule that its own advisory council says may not survive contact with the very EU legal framework it's trying to operate within.

No formal legal challenge has been filed as of this writing, and no timeline exists for when — or whether — one might be. But an official advisory body publicly breaking with government legislation is not routine in Greek policymaking, and the OKE's opinion is being read in Athens as a sign of real friction inside the system over how this law was drafted and rushed through.

Personal Use Still a Criminal Charge

In Greece, penalties for cannabis offenses vary dramatically by severity: personal possession is treated as a minor misdemeanor with a maximum of 5 months imprisonment, while trafficking or felony-level offenses carry a maximum sentence of up to life imprisonment—dramatically harsher.

None of the industrial buildout or the 2026 flower ban touches the law that actually governs an ordinary Greek citizen caught with cannabis for personal use. That law is still Law 4139/2013, and under it, possession of even a small, personal-use quantity remains a misdemeanor carrying up to five months of imprisonment. In practice, first-time offenses are almost always suspended or converted into a fine rather than served as jail time — but the charge is still prosecuted, still goes through the courts, and still leaves a criminal record that can follow someone through background checks, visa applications and employment screening for years.

The penalties escalate sharply once quantity or value crosses certain thresholds. Cases involving trafficking amounts, or where the cannabis involved is valued above 75,000 euros, are treated as felonies, punishable by sentences ranging up to life imprisonment, alongside fines that can reach 300,000 euros. That's a substantial gap between how Greek law treats a patient's prescription bottle and how it treats a grower or dealer moving product outside the licensed system — the personal-use statute sits in an uncomfortable middle zone, criminalizing behavior that in medical contexts the state itself now facilitates and exports.

As of August 2026, no decriminalization or broader legalization bill is actively advancing through the Hellenic Parliament. The legislative energy of the past two years has gone almost entirely into the medical export sector and, more recently, the flower and hemp retail crackdown — not into revisiting the criminal exposure facing ordinary users. That's a deliberate allocation of political attention, whether or not it's been stated as one: cannabis as an export commodity gets ministries, licensing frameworks and public consultations, while cannabis as something an adult might possess for personal use gets left exactly where it was in 2013.

Greece's cannabis policy, taken as a whole, reads less like a coherent national strategy and more like two governments operating in the same building without talking to each other. One is building greenhouses in Examilia, courting foreign pharmacy chains, and defending its export ambitions in front of EU trade lawyers. The other is still sending police to write up misdemeanor charges against people carrying a few grams for themselves, under a statute nobody in Parliament seems inclined to touch.

That arrangement can hold for a while, especially when the export numbers keep climbing and the political incentives all point toward growth rather than reform. But it's an increasingly hard position to defend on its own terms. A government that ships product to pharmacies abroad while prosecuting its own citizens for the same plant is not neutral on cannabis — it has simply decided whose relationship to it counts as legitimate. Until Athens is willing to open up Law 4139/2013 itself, rather than the licensing schedules and export certifications built around it, that decision will keep falling on ordinary Greeks, not on the greenhouses shipping product across the border.